Cargando…

Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease

Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide. Our previous results indicate that the reduced oxidative stress capacity of sickle erythrocytes may be caused by decreased expression of NRF2 (Nuclear factor (erythroid-derived 2)-like 2), an oxidative stress regulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Doss, Jennifer F., Jonassaint, Jude C., Garrett, Melanie E., Ashley-Koch, Allison E., Telen, Marilyn J., Chi, Jen-Tsan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829228/
https://www.ncbi.nlm.nih.gov/pubmed/27071063
http://dx.doi.org/10.1371/journal.pone.0152895
_version_ 1782426720093077504
author Doss, Jennifer F.
Jonassaint, Jude C.
Garrett, Melanie E.
Ashley-Koch, Allison E.
Telen, Marilyn J.
Chi, Jen-Tsan
author_facet Doss, Jennifer F.
Jonassaint, Jude C.
Garrett, Melanie E.
Ashley-Koch, Allison E.
Telen, Marilyn J.
Chi, Jen-Tsan
author_sort Doss, Jennifer F.
collection PubMed
description Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide. Our previous results indicate that the reduced oxidative stress capacity of sickle erythrocytes may be caused by decreased expression of NRF2 (Nuclear factor (erythroid-derived 2)-like 2), an oxidative stress regulator. We found that activation of NRF2 with sulforaphane (SFN) in erythroid progenitors significantly increased the expression of NRF2 targets HMOX1, NQO1, and HBG1 (subunit of fetal hemoglobin) in a dose-dependent manner. Therefore, we hypothesized that NRF2 activation with SFN may offer therapeutic benefits for SCD patients by restoring oxidative capacity and increasing fetal hemoglobin concentration. To test this hypothesis, we performed a Phase 1, open-label, dose-escalation study of SFN, contained in a broccoli sprout homogenate (BSH) that naturally contains SFN, in adults with SCD. The primary and secondary study endpoints were safety and physiological response to NRF2 activation, respectively. We found that BSH was well tolerated, and the few adverse events that occurred during the trial were not likely related to BSH consumption. We observed an increase in the mean relative whole blood mRNA levels for the NRF2 target HMOX1 (p = 0.02) on the last day of BSH treatment, compared to pre-treatment. We also observed a trend toward increased mean relative mRNA levels of the NRF2 target HBG1 (p = 0.10) from baseline to end of treatment, but without significant changes in HbF protein. We conclude that BSH, in the provided doses, is safe in stable SCD patients and may induce changes in gene expression levels. We therefore propose investigation of more potent NRF2 inducers, which may elicit more robust physiological changes and offer clinical benefits to SCD patients. Trial Registration: ClinicalTrials.gov NCT01715480
format Online
Article
Text
id pubmed-4829228
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48292282016-04-22 Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease Doss, Jennifer F. Jonassaint, Jude C. Garrett, Melanie E. Ashley-Koch, Allison E. Telen, Marilyn J. Chi, Jen-Tsan PLoS One Research Article Sickle cell disease (SCD) is the most common inherited hemoglobinopathy worldwide. Our previous results indicate that the reduced oxidative stress capacity of sickle erythrocytes may be caused by decreased expression of NRF2 (Nuclear factor (erythroid-derived 2)-like 2), an oxidative stress regulator. We found that activation of NRF2 with sulforaphane (SFN) in erythroid progenitors significantly increased the expression of NRF2 targets HMOX1, NQO1, and HBG1 (subunit of fetal hemoglobin) in a dose-dependent manner. Therefore, we hypothesized that NRF2 activation with SFN may offer therapeutic benefits for SCD patients by restoring oxidative capacity and increasing fetal hemoglobin concentration. To test this hypothesis, we performed a Phase 1, open-label, dose-escalation study of SFN, contained in a broccoli sprout homogenate (BSH) that naturally contains SFN, in adults with SCD. The primary and secondary study endpoints were safety and physiological response to NRF2 activation, respectively. We found that BSH was well tolerated, and the few adverse events that occurred during the trial were not likely related to BSH consumption. We observed an increase in the mean relative whole blood mRNA levels for the NRF2 target HMOX1 (p = 0.02) on the last day of BSH treatment, compared to pre-treatment. We also observed a trend toward increased mean relative mRNA levels of the NRF2 target HBG1 (p = 0.10) from baseline to end of treatment, but without significant changes in HbF protein. We conclude that BSH, in the provided doses, is safe in stable SCD patients and may induce changes in gene expression levels. We therefore propose investigation of more potent NRF2 inducers, which may elicit more robust physiological changes and offer clinical benefits to SCD patients. Trial Registration: ClinicalTrials.gov NCT01715480 Public Library of Science 2016-04-12 /pmc/articles/PMC4829228/ /pubmed/27071063 http://dx.doi.org/10.1371/journal.pone.0152895 Text en © 2016 Doss et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Doss, Jennifer F.
Jonassaint, Jude C.
Garrett, Melanie E.
Ashley-Koch, Allison E.
Telen, Marilyn J.
Chi, Jen-Tsan
Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
title Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
title_full Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
title_fullStr Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
title_full_unstemmed Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
title_short Phase 1 Study of a Sulforaphane-Containing Broccoli Sprout Homogenate for Sickle Cell Disease
title_sort phase 1 study of a sulforaphane-containing broccoli sprout homogenate for sickle cell disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4829228/
https://www.ncbi.nlm.nih.gov/pubmed/27071063
http://dx.doi.org/10.1371/journal.pone.0152895
work_keys_str_mv AT dossjenniferf phase1studyofasulforaphanecontainingbroccolisprouthomogenateforsicklecelldisease
AT jonassaintjudec phase1studyofasulforaphanecontainingbroccolisprouthomogenateforsicklecelldisease
AT garrettmelaniee phase1studyofasulforaphanecontainingbroccolisprouthomogenateforsicklecelldisease
AT ashleykochallisone phase1studyofasulforaphanecontainingbroccolisprouthomogenateforsicklecelldisease
AT telenmarilynj phase1studyofasulforaphanecontainingbroccolisprouthomogenateforsicklecelldisease
AT chijentsan phase1studyofasulforaphanecontainingbroccolisprouthomogenateforsicklecelldisease